Treatment outcomes of hepatic and pulmonary metastases from colorectal carcinoma

被引:30
作者
Lee, Won-Suk [1 ]
Yun, Hae-Ran [1 ]
Yun, Seong-Hyeon [1 ]
Chun, Ho-Kyung [1 ]
Lee, Woo-Yong [1 ]
Kim, Sung-Joo [1 ]
Choi, Seong-Ho [1 ]
Heo, Jin-Seok [1 ]
Joh, Jae-Won [1 ]
Park, Young-Suk [2 ]
Kang, Won-Ki [2 ]
机构
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Surg, Seoul 135710, South Korea
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med, Seoul 135710, South Korea
关键词
colon cancer; liver metastasis; lung metastasis; survival;
D O I
10.1111/j.1440-1746.2007.05178.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and Aim: The resection of synchronous or metachronous pulmonary and liver metastasis is an aggressive treatment option for patients with stage IV colorectal cancer and has been shown to yield acceptable long-term survival. We reviewed our experience with colorectal cancer patients with both liver and lung resections to determine the efficacy of surgical resections. Methods: We performed a single institution, retrospective analysis of all patients who underwent surgical hepatic and pulmonary resection for metastatic colorectal cancer between 1995 and 2004. Results: A total of 32 patients underwent resection of both hepatic and pulmonary metastases secondary to colorectal cancer. The 5-year overall survival from initial operation was 60.8%. The disease-free interval was 44.3 months (95% confidence interval: 24.7 and 63.8, respectively). Neither the number of pulmonary lesions nor the time interval between the primary surgery and the metastasectomy had a significant impact on survival (P = 0.134). Conclusion: An aggressive surgical treatment of selected colorectal cancer patients with lung and liver metastases resulted in prolonged survival. The 5-year survival rate of 60.8% with no perioperative mortality was observed in our study.
引用
收藏
页码:E367 / E372
页数:6
相关论文
共 38 条
[1]  
Adam R, 2001, ANN SURG ONCOL, V8, P347
[2]  
Ambiru S, 1998, CANCER, V82, P274, DOI 10.1002/(SICI)1097-0142(19980115)82:2<274::AID-CNCR5>3.0.CO
[3]  
2-R
[4]   Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen [J].
André, T ;
Bensmaine, MA ;
Louvet, C ;
François, E ;
Lucas, V ;
Desseigne, F ;
Beerblock, K ;
Bouché, O ;
Carola, E ;
Merrouche, Y ;
Morvan, F ;
Dupon-André, G ;
de Gramont, A .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3560-3568
[5]   CLINICAL PERSPECTIVE OF HUMAN COLORECTAL-CANCER METASTASIS [J].
AUGUST, DA ;
OTTOW, RT ;
SUGARBAKER, PH .
CANCER AND METASTASIS REVIEWS, 1984, 3 (04) :303-324
[6]  
Avital Itzhak, 2006, Thorac Surg Clin, V16, P145, DOI 10.1016/j.thorsurg.2005.12.002
[7]   XELOX (capecitabine plus oxaliplatin):: Active first-line therapy for patients with metastatic colorectal cancer [J].
Cassidy, J ;
Tabernero, J ;
Twelves, C ;
Brunet, R ;
Butts, C ;
Conroy, T ;
Debraud, F ;
Figer, A ;
Grossmann, J ;
Sawada, N ;
Schöffski, P ;
Sobrero, A ;
Van Cutsem, E ;
Diaz-Rubio, E .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) :2084-2091
[8]   Hepatocellular carcinoma treated with percutaneous radio-frequency ablation: Usefulness of power Doppler US with a microbubble contrast agent in evaluating therapeutic response-preliminary results [J].
Choi, D ;
Lim, HK ;
Kim, SH ;
Lee, WJ ;
Jang, HJ ;
Lee, JY ;
Paik, SW ;
Koh, KC ;
Lee, JH .
RADIOLOGY, 2000, 217 (02) :558-563
[9]   Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J].
de Gramont, A ;
Figer, A ;
Seymour, M ;
Homerin, M ;
Hmissi, A ;
Cassidy, J ;
Boni, C ;
Cortes-Funes, H ;
Cervantes, A ;
Freyer, G ;
Papamichael, D ;
Le Bail, N ;
Louvet, C ;
Hendler, D ;
de Braud, F ;
Wilson, C ;
Morvan, F ;
Bonetti, A .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2938-2947
[10]   Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer - Analysis of 1001 consecutive cases [J].
Fong, Y ;
Fortner, J ;
Sun, RL ;
Brennan, MF ;
Blumgart, LH .
ANNALS OF SURGERY, 1999, 230 (03) :309-318